Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$28.06
+0.7%
$24.63
$12.00
$28.78
$4.45B2.091.92 million shs4.00 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$285.15
+2.2%
$266.78
$144.26
$303.30
$13.32B1.4856,887 shs1.11 million shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$630.19
+1.0%
$589.62
$373.00
$677.90
$17.42B1.15210,078 shs303,001 shs
Revvity Inc. stock logo
RVTY
Revvity
$143.27
-0.2%
$121.92
$81.22
$149.52
$16.02B1.091.92 million shs2.86 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+0.72%+5.17%+7.96%+45.09%+101.29%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+1.95%+4.46%-3.41%+40.99%+85.49%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+0.96%+1.56%+1.52%+23.08%+26.52%
Revvity Inc. stock logo
RVTY
Revvity
-0.27%+2.32%+14.73%+35.33%+65.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$28.06
+0.7%
$24.63
$12.00
$28.78
$4.45B2.091.92 million shs4.00 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$285.15
+2.2%
$266.78
$144.26
$303.30
$13.32B1.4856,887 shs1.11 million shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$630.19
+1.0%
$589.62
$373.00
$677.90
$17.42B1.15210,078 shs303,001 shs
Revvity Inc. stock logo
RVTY
Revvity
$143.27
-0.2%
$121.92
$81.22
$149.52
$16.02B1.091.92 million shs2.86 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+0.72%+5.17%+7.96%+45.09%+101.29%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+1.95%+4.46%-3.41%+40.99%+85.49%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+0.96%+1.56%+1.52%+23.08%+26.52%
Revvity Inc. stock logo
RVTY
Revvity
-0.27%+2.32%+14.73%+35.33%+65.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.57
Moderate Buy$27.07-3.52% Downside
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.67
Moderate Buy$273.81-3.98% Downside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.25
Hold$595.20-5.55% Downside
Revvity Inc. stock logo
RVTY
Revvity
2.22
Hold$116.57-18.63% Downside

Current Analyst Ratings Breakdown

Latest ADPT, MEDP, RVTY, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Set Price Target$34.00
9/22/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Boost Price TargetBuy$25.00 ➝ $34.00
9/17/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$330.00
9/14/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Reiterated RatingHold
9/11/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Reiterated RatingOutperform$320.00
9/9/2026
Revvity Inc. stock logo
RVTY
Revvity
Initiated CoverageBuyNeutral$120.00 ➝ $140.00
9/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetOverweight$125.00 ➝ $165.00
9/1/2026
Revvity Inc. stock logo
RVTY
Revvity
Initiated CoverageSector Perform$135.00
9/1/2026
Revvity Inc. stock logo
RVTY
Revvity
Initiated CoverageSector Perform$135.00
8/12/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
UpgradeHold (C+)Buy (B-)
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetBuy$235.00 ➝ $300.00
(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$276.98M16.17N/AN/A$1.47 per share19.09
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.39$22.44 per share12.71$64.39 per share4.43
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.53B6.95$17.18 per share36.69$16.30 per share38.66
Revvity Inc. stock logo
RVTY
Revvity
$2.86B5.60$8.79 per share16.29$63.95 per share2.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.41N/AN/AN/A-20.73%-36.81%-13.77%11/4/2026 (Estimated)
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A22.582.74-5.96%15.75%6.51%11/4/2026 (Estimated)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.12M$17.0636.9432.872.7817.67%110.15%24.84%10/28/2026 (Estimated)
Revvity Inc. stock logo
RVTY
Revvity
$241.20M$2.1068.2224.322.618.16%8.34%5.01%10/26/2026 (Estimated)

Latest ADPT, MEDP, RVTY, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
8/4/2026Q2 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.21$1.41+$0.20$0.47$702.96 million$729.69 million
7/29/2026Q2 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.1336-$0.25-$0.1164-$0.25$65.44 million$71.55 million
7/22/2026Q2 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.98$4.25+$0.27$4.25$689.51 million$707.33 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
Revvity Inc. stock logo
RVTY
Revvity
$0.280.20%N/A13.33%N/A

Latest ADPT, MEDP, RVTY, and CRL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Revvity Inc. stock logo
RVTY
Revvity
quarterly$0.070.25%10/23/202610/23/202611/13/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.22
4.79
4.68
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.73
0.73
Revvity Inc. stock logo
RVTY
Revvity
0.36
1.80
1.50

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
Revvity Inc. stock logo
RVTY
Revvity
86.65%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.50%
Revvity Inc. stock logo
RVTY
Revvity
0.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
624159.60 million150.50 millionOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
6,20027.91 million22.19 millionOptionable
Revvity Inc. stock logo
RVTY
Revvity
11,000111.59 million110.64 millionOptionable

Recent News About These Companies

Insider Selling: Revvity (NYSE:RVTY) Insider Sells $1,032,650.40 in Stock
Financial Comparison: Revvity (NYSE:RVTY) and Cytek Biosciences (NASDAQ:CTKB)
Revvity (NYSE:RVTY) Insider Sells $1,032,650.40 in Stock
Revvity extends gains with another 9% advance, sets new high
Revvity Jumps 6.1% Amid Sector-Wide Rally
Revvity (NYSE:RVTY) Reaches New 1-Year High - What's Next?
Amundi Trims Holdings in Revvity Inc. $RVTY
Revvity (RVTY) Receives a New Rating from UBS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$28.06 +0.20 (+0.72%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$28.01 -0.05 (-0.18%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$285.15 +6.14 (+2.20%)
Closing price 09/22/2026 03:59 PM Eastern
Extended Trading
$285.74 +0.59 (+0.21%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Medpace stock logo

Medpace NASDAQ:MEDP

$630.19 +5.99 (+0.96%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$628.00 -2.19 (-0.35%)
As of 07:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Revvity stock logo

Revvity NYSE:RVTY

$143.27 -0.32 (-0.22%)
Closing price 09/22/2026 03:59 PM Eastern
Extended Trading
$143.25 -0.02 (-0.01%)
As of 08:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.